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An unusual cytogenetic rearrangement, described as ins(22;9)(q11;q34q21), was detected in a 49-
year-old male patient diagnosed with chronic myeloid leukemia (CML). Reverse transcriptase
polymerase chain reaction (RT-PCR) revealed a b3a2 fusion transcript. In order to confirm the cy-
togenetic findings and fully characterize the inverted insertion, we performed fluorescence in situ
hybridization (FISH) assays using locus-specific and whole chromosome painting probes. Our




 fusion gene, verified the insertion and deter-















Chronic myeloid leukemia (CML) is cytogenetically
characterized by the presence of the Philadelphia chromo-
some (Ph), which results from a reciprocal t(9;22)(q34;q11)
translocation and is found in about 90–95% of CML pa-
tients. The molecular consequence of the t(9;22) is the fu-





















 gene, which encodes a fusion protein with
prominent tyrosine kinase activity and transforming ability
[1]. Ph variants are found in 5% of CML patients. Such
variants consist of complex translocations among three or
more chromosomes including 9 and 22 and sometimes re-





[2]. In these cases, fluorescence in situ hybridization (FISH)





 fusion gene [3]. Here, we present the characterization
by FISH of a complex inverted insertion of chromosome 9
into chromosome 22 in a case of CML.
 




In January 1999, a 49-year-old man was referred to the
Department of Hematology of the Hospital Miguel Servet
(Zaragoza, Spain) for evaluation of fatigue, weight loss, and
abdominal discomfort. Physical examination revealed a pal-
pable abdominal mass in the left side, 12 cm below costal
limits. Neither the personal nor the familiar history showed
relevant data. Hematological parameters were as follows:


















blood (MGG stain) with 25% neutrophils, 17% band, 13%
metamyelocytes, 32% myelocytes, 4% promyelocytes, 2%
blasts, 1% eosinophils, 4% basophils, and 2% lymphocytes.
Leukocyte alcaline phosphatase score was reduced to 4. All
laboratory values were normal with the exception of high
levels of lactate deshydrogenase (1151 UI/L, normal below




 vitamin levels (7329 pg/mL, normal
180–900 pg/mL). Bone marrow aspirate showed hypercel-
lularity with myeloid hyperplasia (94.2%), including 2.8%
myeloblasts, and 2.8% basophils. Decreased erythropoiesis
(2%) and increased number of hypolobulated and small size
megakaryocytes. Bone marrow biopsy showed marked hy-
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percellularity with loss of fat spaces and mild reticulin fi-
brosis of irregular distribution. Abdominal ultrasonography
confirmed splenomegaly. Cytogenetic analysis at diagnosis
revealed a t(9;22) variant, ins(22;9)(q11;q34q21), and the
presence of a b3a2 fusion transcript was detected by reverse
transcriptase polymerase chain reaction (RT-PCR). The pa-
tient was diagnosed as Philadelphia positive CML at stage 3
of Kantarjian. To additionally characterize this rare cytoge-
netic finding, we initiated FISH studies.
Cytoreduction was started with hydroxyurea 2 g qid po
until decreased WBC counts and spleen size were evident.
One month later the administration of alfa-Interferon [4], 3
mU qid sc was initiated with escalating doses until 9 mU




 10 days every 4
weeks. Six months later a partial hematological remission
was achieved with normal WBC counts, normal leukocyte
differential distribution, and spleen size reduced to 50% of
initial value. To date, 16 months after the diagnosis, the pa-
tient has remained stable in a chronic phase with partial he-
matological remission; a cytogenetic response has not ap-
peared yet.
 
2.2. Cytogenetic analysis, FISH and RT-PCR
 
Chromosomal analysis of tumor cells was performed on
bone marrow. Samples were processed using standard short-
term unstimulated cultures. Metaphases were G-banded ac-
cording to a conventional trypsin-Giemsa procedure.
FISH was performed according to manufacturer’s in-
structions using: whole painting probes for chromosomes 9
and 22 labeled with fluorescein (FITC) and cyanine 3
(Cy3), respectively (Cambio, Cambridge, UK), and two lo-












 (SO)/ARSA (SG) genes
(Vysis, Downers Grove, IL, USA). Cytogenetic and FISH
data were described according to the International System
for Human Cytogenetic Nomenclature [5].




A total of 50 metaphases were evaluated and in all of
them, the karyotype was described as: 46,XY,der(9)t(9;
22)(q13;q11),der(22)ins(22;9)(q11;q34q21). As it can be
observed in Fig. 1, the derivative chromosome 22 contains a





















 signals are located close to the centromere (4B
and 4C). The derivative chromosome 9 contains part of














shown). According to these findings, the derivative chro-























































). Fig. 1 shows
the ideograms of both normal and derivative chromosomes
9 and 22 and the chromosome pictures after G-banding,





DiGeorge probes. A b3a2 mRNA transcript was found by
RT-PCR indicating that the breakpoint was located within








Philadelphia chromosome cytogenetic variants in CML
are becoming easily characterized using FISH techniques
[2,7]. These t(9;22) variants usually involve a third chromo-
some and complex rearrangements involving only chromo-
somes 9 and 22 have been rarely described [8–10]. Like




fusion, which can be confirmed by RT-PCR [11]. The clini-
cal course of these patients does not differ from that of pa-
tients carrying the classical t(9;22) [2]. Cytogenetic re-





 [12]. In our patient, although a partial
hematological remission was achieved, the cytogenetic re-





. We performed a complete genetic analysis of leuke-
mic cells from this CML patient and found a complex bal-
anced rearrangement between chromosomes 9 and 22 with-
out the Philadelphia chromosome, but with molecular




 fusion gene. G-banding kary-
otyping revealed a large derivative chromosome 22 and a
short derivative chromosome 9, which were described as:
46,XY,der(9)t(9;22)(q13;q11),der(22)ins(22;9)(q11;q34q21).
Fig. 1 shows both normal 9 and 22 chromosomes (I), the
different fragments after chromosome breakage (II), and
the complex alteration (III) as they were seen by the differ-






 (4B) signal is located near the
centromere on the der(22) thus confirming the inverted in-
sertion we had proposed initially. To locate the second









, and found that this gene was re-
tained on 22q11 (4C), hence the region where the 9q seg-
ment was inserted must be between those two genes. Ac-
cording to the genomic sequence of chromosome 22 (http://
www.sanger.ac.uk/HGP/Chr22/), our findings suggest that
the breakpoint must be approximately in a region between
3.2 Mb (TUPLE1) and 7.1 Mb (BCR) from the centromere.
Although we had cytogenetically described the der(22) as a
simple ins(22;9)(q11;q3421), after FISH, the description














In order to explain the genesis of this variant t(9;22), we
propose two hypotheses: a two-step mechanism, in which a
classical t(9;22) took place followed by an inverted inser-
tion of an interstitial segment of the der(9) into the proximal
region of the Philadelphia chromosome; or a single-step
mechanism, in which all the fragments were split and rear-
ranged in a complex fashion at the same time. The first hy-
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pothesis could not be confirmed because at diagnosis the
patient did not have a Ph chromosome; it is possible that the
clone with the insertion had a proliferative advantage over
the clone with the t(9;22), due perhaps to a second fusion
between genes involved in the insertion. Another possible
explanation that we can not rule out is that both the translo-
cation and the insertion took place as a two-step mechanism
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